Tag: CytomX Therapeutics Inc (CTMX)

Questions & Answers

The Week in Review #51 Questions & Answers About CytomX Q: Is there any reason for the CytomX stock selloff that occurred in early May? In order to answer this question we need to explain CytomX’s (CTMX) Probody therapeutics. These novel treatments are designed to remain inactive until they are activated only . . . This content is for paid subscribers. Please click here to subscribe …

The Time Has Come for This Small Biotech Firm to Grow and Thrive

CytomX Therapeutics CytomX (CTMX) is a clinical-stage oncology-focused biopharmaceutical company developing a novel class of investigational antibody therapeutics based on the firm’s Probody® technology platform for cancer treatments. CytomX’s Probody therapeutics remain inactive until they are activated by proteases in the tumor microenvironment.   Why This is Important By remaining inactive until activated by the cancers’ microenvironment’s proteases, the Probody therapeutics minimizes the active drug’s toxicity …
Tracing Large Pharmaceutical Companies’ Choices

Tracing Large Pharmaceutical Companies’ Choices

The Week in Review #8 Potential biotech winners inspired through COLLABORATION - When successful top-­tier drug developing firms such as Amgen (AMGN) or Merck (MRK) sign strategic collaborating agreements with small development-­stage biotech firms,...   &nbsp . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
New Breakthrough Immuno-Oncology Products

New Breakthrough Immuno-Oncology Products

The Week in Review #7 A lot more happened in the past week regarding improving the treatment of cancer and of other devastating diseases. This issue contains discoveries that aim at improving breakthrough immuno-­oncology treatment outcomes. Here are some of the breakthrough technologies and treatments that might improve, by-­far, the management of cancer . . . This content is for paid subscribers. Please click here to …
Prohost Letter #408

Prohost Letter #408

Prohost Letter #408 AT A GLANCE - Continued from the Previous Prohost Letter #408 In the Past issue #407, we picked the following firms: NEUROCRINE BIOSCIENCES (NBIX) Treating Tardive Dyskinesia CYTOMX Improving On Cancer Immunotherapy CELYAD SA (CYAD) Bringing Solutions To Immunotherapy Problems Please Read the articles written about these firms in the Issue #407 In This Issue We Add  NEW LINK GENETICS...
Prohost Letter #407

Prohost Letter #407

Prohost Letter #407 AT A GLANCE - Firms Added to Prohost Portfolio PROHOST IS PICKING NEUROCRINE BIOSCIENCES   On March 27, a few days before the FDA approves Neurocrine’s (NBIX) drug Ingrezza, (valbenazine) capsules for adults with tardive dyskinesia (TD), we posted an article titled “Time for Transformation and Achievements”. In the article, we stated that Neurocrine Sciences Ingrezza will highlight Neurocrine Biosciences and its …
CytomX Therapeutics: A Noteworthy Expansion of Collaborative Agreement with BMY

CytomX Therapeutics: A Noteworthy Expansion of Collaborative Agreement with BMY

Everybody knows Bristol-Myers Squibb (BMY), but just a few may know anything about CytomX Therapeutics (CTMX), or about its Probody Program. CytomX is a small, develop-ment-stage firm that created platform known as the Probody Program, which leads to the creation of first in class Probody therapeutics. These therapeutics are meant to overcome safety and efficacy problems encountered by the antibodies that are currently used in …